Strides Pharma Science’s arm, Pii get nod for Potassium Chloride Extended-Release Tablets
2nd Apr 2019

Strides Pharma Science’s step-down wholly owned subsidiary -- Vensun Pharmaceuticals, Inc., USA and its partner Pharmaceutics International, Inc. (Pii) have received approval for jointly developed Potassium Chloride Extended-Release Tablets USP, 10 mEq (750 mg), 15 mEq (1,125 mg), and 20 mEq (1,500 mg) product from the United States Food & Drug Administration (USFDA).

The product is an immediately dispersing extended-release oral dosage form of potassium chloride and is a generic version of Potassium Chloride Extended-Release Tablets of Merck, Inc. According to IQVIA MAT data, the US market for Potassium Chloride Extended Release Tablets with the current reference product is approximately $ 240 million. The product will be manufactured by Pii and will be marketed by Strides in the US market.

Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.